Login to Your Account



When worlds colloid: CSL albumin factor IX winner in three phase III studies

By Randy Osborne
Staff Writer

Thursday, June 25, 2015
With "fivefold increase in half-life" and "no safety complications whatsoever," CSL Behring's long-acting fusion protein that links recombinant coagulation factor IX with recombinant albumin (rIX-FP) "is going to benefit patients in an extraordinary way," Debra Kennedy, head of coagulant and oncology therapeutics, told BioWorld Today.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription